Staying Up to Date on the Treatment of Advanced HR-Positive, HER2-Negative Breast Cancer
This activity contains:
- CME/CPE/CNE-Certified Live Grand Rounds and Webinars
- Downloadable Slide Deck with Facilitator’s Guide
(a non-certified educational resource)
The goal of this activity is to provide physicians, nurses, pharmacists, and other healthcare professionals with an understanding of the latest clinical advances on the therapeutic options for the treatment of advanced HR-positive, HER2-negative breast cancer.
Breast cancers that are hormone receptor (HR) positive and human epidermal growth factor receptor 2 (HER2) negative represent the most common subtype of breast cancer. Nearly 80% of patients with advanced breast cancer have the HER2-negative subtype and therefore are not candidates for HER2-targeting therapies. Endocrine therapy is currently the cornerstone of treatment for advanced HR-positive breast cancer. However, not all patients respond to first-line endocrine therapy, and those that do respond eventually experience disease relapse. Resistance to endocrine therapy is common, and complete disease resistance to additional endocrine therapy eventually develops in patients with HR-positive metastatic breast cancer (MBC). The 5-year and 10-year survival rates for MBC are 26% and 5% to 10%, respectively. Significant therapeutic advances in this area include the development of agents that target critical pathways involved in the development of resistance to endocrine therapy. These include mechanistic target of rapamycin (mTOR) inhibitors and cyclin-dependent kinase (CDK) 4/6 inhibitors.
This activity will review the mechanisms of action, efficacy, and safety of different classes of therapies, such as mTOR inhibitors and CDK 4/6 inhibitors, used in the treatment of advanced HR-positive, HER2-negative breast cancer so that clinicians can incorporate these therapies into their treatment plans for patients.
- Activity Overview (5 min)
- Overview of HR-positive, HER2-negative breast cancer (5 min)
- The role of mTOR inhibitors (15 min)
- The role of CDK 4/6 inhibitors (15 min)
- Strategies for optimal use of mTOR inhibitors and CDK 4/6 inhibitors in the treatment of advanced HR-positive, HER2-negative breast cancer (10 min)
- Interactive Case Challenges (10 min)
This activity is intended for physicians, nurses, pharmacists, and other healthcare professionals who manage breast cancer.
At the conclusion of this activity, participants should be better able to:
- Differentiate the mechanisms of action of mTOR inhibitors and CDK 4/6 inhibitors
- Summarize the efficacy and safety data for mTOR inhibitors and CDK 4/6 inhibitors in the setting of advanced HR-positive, HER2-negative breast cancer
- Identify the clinical circumstances in which an mTOR inhibitor or a CDK 4/6 inhibitor would be an appropriate treatment option for a patient with breast cancer
- Summarize strategies for effectively managing adverse events and facilitating patient adherence to therapy
Harold J. Burstein, MD, PhD
|William J. Gradishar, MD, FASCO, FACP|
Betsy Bramsen Professor of Breast Oncology
Director, Maggie Daley Center for Women's Cancer Care
Deputy Director, Robert H. Lurie Comprehensive Cancer Center Northwestern University
Virginia G. Kaklamani, MD, DSc
Ruth O'Regan, MD
|Priya Rastogi, MD|
Sr. Associate Medical Director. NSABP Medical Affairs
Associate Professor of Medicine, UPMC Cancer Institute
|Antoinette R. Tan, MD, MHSc|
Chief of Breat Medical Oncology
Co-Director of the Phase I Program
Levine Cancer Institute
Carolinas Healthcare System
Clinincal Professor, Department of Medicine
University of North Carolina
|Deborah L. Toppmeyer, MD|
Chief Medical Officer, Chief of Medical Oncology
Director, Stacy Goldstein Breast Cancer Center
Professor of Medicine
Rutgers Robert Wood Johnson Medical School
New Brunswick, NY
In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Credit Designation for Physicians
AXIS Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Credit Designation for Pharmacists
This application-based activity is approved for 1.0 contact hour of continuing pharmacy education credit. UAN 0592-0000-16-040-L01-P.
Credit Designation for Nursing
AXIS Medical Education designates this continuing nursing education activity for 1.0 contact hour.
Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.
California Board of Registered Nursing
AXIS is approved by the California Board of Registered Nursing, Provider Number 16702, for 1.0 contact hour.
Iowa Board of Nursing
AXIS is Iowa Board of Nursing approved provider number 371. This program is awarded 1.0 contact hour.
Disclosure of Conflicts of Interest
AXIS Medical Education requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
AXIS will identify, review, and resolve all conflicts of interest that faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.
The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:
|Name of Faculty or Presenter||Reported Financial Relationship|
|Harold J. Burstein, MD, PhD||Harold J. Burstein, MD, PhD, has no real or apparent conflicts of interest to report.|
|William J. Gradishar, MD, FASCO, FACP||William J. Gradishar, MD, FACP, has no real or apparent conflicts of interest to report.|
Virginia G. Kaklamani, MD, DSc
|Virginia G. Kaklamani, MD, DSc, reported a financial interest/relationship or affiliation in the form of: Advisory board: Celgene Corp; Eisai Inc, Genomic Health, Inc; Research grant: Eisai Inc.|
|Ruth O’Regan, MD||Ruth M. O'Regan, MD, reported a financial interest/relationship or affiliation in the form of Research grant, Eisai Inc, Pfizer, Inc, Novartis Pharmaceuticals Corp; Contracted research paid, Eisai Inc, Biotheranostics, Lilly USA, Pfizer, Inc, Atossa Genetics|
|Priya Rastogi, MD||Priya Rastogi, MD, has no real or apparent conflicts of interest to report.|
|Antoinette R. Tan, MD, MHSc||Antoinette R. Tan, MD, MHSc reported a financial interest/relationship or affiliation in the form of Advisory Board, Abbvie, Merch, and Pfizer.|
|Deborah L. Toppmeyer, MD||Deborah L. Toppmeyer, MD, Employment, Novartis Pharmaceuticals Corp (spouse).|
The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:
The following AXIS planners and managers, Linda-Gracie-King, MS, Ronald Viggiani, MD, Jocelyn Timko, and Marilyn Haas, PhD, RN, CNS, ANP-BC hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months. Stephanie Sutphin, PharmD reports a financial interest/relationship or affiliation in the form of Advisory board: Seattle Genetics and Amgen Biosimilars.
This activity is supported by educational grants from Novartis Pharmaceuticals and Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com
There is no fee for this educational activity.
This activity is provided by:
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Attendance